OBJECTIVE: We previously demonstrated that a combination of mild @entity706 ( @entity706 ) with selective depletion of the host's donor-reactive cells allows for stable and @entity2132 ( @entity2132 )-free engraftment of allogeneic bone marrow (BM). In this study, we investigated the efficacy of this nonmyeloablative strategy for BM transplantation (BMT) as immunotherapy for @entity41 . MATERIALS AND METHODS: BALB/c @entity19 inoculated with @entity1778 ( @entity1896 ) or @entity0 (4T1) cells were conditioned for BMT with @entity706 (200 cGy) followed by priming with donor (C57BL/6) BM cells on day 1, and by injection with 200 mg/kg @entity786 on day 2. After conditioning (day 3), recipients were transplanted with BM cells from the same donor. Treated animals were monitored for 230 days for survival, development of @entity1778 /solid @entity5 , and @entity2132 . RESULTS: BMT converted the @entity19 to complete chimeras and prevented development of @entity1778 in 90% of recipients and locally growing @entity0 in 40% of the @entity19 . Immunization of donors of the second BM with 4T1 cells prevented development of @entity0 in 80% of 4T1 inoculated @entity19 . Fewer animals treated for @entity5 by nonmyeloablative BMT died of @entity2132 than those treated by myeloablative BMT. However, late @entity2132 -related mortality in @entity19 treated for @entity1778 was higher than after nonmyeloablative BMT to naive recipients (p < 0.00001). Infusion of host-type anti-donor immune lymphocytes 8 days after BMT improved the survival of recipients treated for @entity1778 without affecting engraftment and the graft-vs- @entity1778 potential of donor BM. CONCLUSIONS: Effective eradication of malignant cells can be achieved following allogeneic BMT after nonmyeloablative conditioning.

Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic XXXX in preclinical models.

@entity1896 :: ('12443(Tax:10090)', 'Gene') :: ['BCL1'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast carcinoma'] @entity41 :: ('MESH:D018365', 'Disease') :: ['minimal residual disease'] @entity706 :: ('MESH:D008223', 'Disease') :: ['TLI', 'total lymphoid irradiation'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignancy'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'graft-vs-host disease']
@entity5 :: (MESH:D009369,Disease) :: ['solid tumors']
